- Home
- NUVL vs CHDN Comparison
NUVL vs CHDN Comparison
Compare NUVL & CHDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUVL | CHDN |
|---|---|---|
| Founded | 2017 | 1928 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.9B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | NUVL | CHDN |
|---|---|---|
| Price | $103.62 | $87.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | $134.75 | ★ $135.60 |
| AVG Volume (30 Days) | 543.5K | ★ 748.7K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.50% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.49 |
| Revenue | N/A | ★ $1,809,800,000.00 |
| Revenue This Year | N/A | $5.61 |
| Revenue Next Year | $1,235.73 | $3.53 |
| P/E Ratio | ★ N/A | $15.93 |
| Revenue Growth | N/A | ★ 13.31 |
| 52 Week Low | $63.56 | $81.66 |
| 52 Week High | $113.02 | $118.46 |
Technical Indicators
Market Signals| Indicator | NUVL | CHDN |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 48.46 |
| Support Level | $97.63 | $86.50 |
| Resistance Level | $107.08 | $88.33 |
| Average True Range (ATR) | 3.66 | 2.51 |
| MACD | 0.56 | 0.42 |
| Stochastic Oscillator | 72.56 | 51.48 |
Price Performance
Historical ComparisonAbout NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CHDN Churchill Downs Incorporated
Churchill Downs Inc is a gaming entertainment, online wagering, and racing company. It operates through three business segments: Live and Historical Racing, Wagering Services, and Gaming. The Live and Historical Racing segment includes live and historical pari-mutuel racing. The Wagering Services segment includes the revenue and expenses from pari-mutuel wagers through TwinSpires, companies retail and online sports betting business and Gaming segment includes revenue and expenses for the casino properties and associated racetracks that support the casino license. The Gaming segment generates revenue and expenses from slot machines, video lottery terminals, video poker, HRMs, ancillary food and beverage services, hotel services, commission on pari-mutuel wagering, and racing events.